Cardiovascular effects of SGLT‐2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cardiovascular effects of SGLT‐2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand

Published:2019-01-16 Issue:4 Volume:35 Page:e3124
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Cavallari Ilaria¹^ORCID,Maddaloni Ernesto²³^ORCID

Affiliation:

1. Department of Cardiovascular ScienceCampus Bio‐Medico University of Rome Rome Italy

2. Department of Medicine, Unit of Endocrinology and DiabetesCampus Bio‐Medico University of Rome Rome Italy

3. Experimental MedicineSapienza University of Rome Italy

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.3124

Reference13 articles.

1. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

2. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs

3. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

4. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

5. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2023-02-14

2. SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness;American Journal of Cardiovascular Drugs;2021-11-17

3. Association Between SGLT2 Inhibitors vs DPP-4 Inhibitors and Risk of Pneumonia Among Patients With Type 2 Diabetes;The Journal of Clinical Endocrinology & Metabolism;2021-11-08

4. Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease;Frontiers in Pharmacology;2021-05-12

5. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study;Diabetes Research and Clinical Practice;2021-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3